CJC-1295 / Ipamorelin (No Dac)
This is a combination research blend sold as one vial: CJC-1295 without DAC, a copy of growth hormone-releasing hormone, plus Ipamorelin, a short peptide that acts on the ghrelin receptor. It is studied as a GHRH and GHRP pairing in growth-hormone research.
This is a combination sold as one vial. It has not been studied as a single substance, so what is known is what is known about each part, linked above. Sources that report a dose for the blend report it for that mixture, not for any component on its own.
At a glance
- CJC-1295 5mg / Ipamorelin 5mg (No Dac) 10mg
- Protocol component
- Not yet audited here; the reference library calls it emerging
- Sources differ. See the source
How much to draw
Full calculator →The reference does not report a single injectable amount for CJC-1295 / Ipamorelin (No Dac), so the amount is yours to enter. The arithmetic is the same for any vial. How to reconstitute a vial.
What sources report
These are figures published elsewhere, reproduced with their source. Peppersite does not recommend an amount for CJC-1295 / Ipamorelin (No Dac) or for anything else, and nothing below has been checked against the study it came from.
| Amount | Frequency | Route | Reported by |
|---|---|---|---|
| 200-300 mcg of each peptide daily, typically administered once daily SubQ. | not stated | not stated | Peptide Dosing Protocols stack |
- not stated
- not stated
- Peptide Dosing Protocols stack
- Add 3.0 mL BAC water to a 20 mg blend vial.
We have not published an audit on CJC-1295 / Ipamorelin (No Dac). Everything below is reference material, not our own reading of the literature, treat it as a starting point for questions, not as a grade.
How it is thought to work
One part tells the pituitary gland to make growth hormone, and the other tells the same cells to release it, through a completely separate receptor. Researchers link this to the GHRH receptor on pituitary somatotrophs and the ghrelin receptor (GHSR1a); a 2002 study by Cunha and Mayo in Endocrinology reported that ghrelin-receptor signalling strengthens GHRH signalling on the same cell, so the two multiply rather than add. The no-DAC form is the one paired here because its 30-minute to 2-hour half-life matches Ipamorelin's roughly 2-hour half-life and keeps release in natural pulses. No published human randomised trial has tested the combination at the daily 200-300 mcg doses common in research planning, and FDA review documents from October 2024 noted the limited clinical data.
Reported side effects
Reported by users: facial flushing or warmth in the first 5-10 minutes after an injection, described as more common with CJC-1295 than Ipamorelin; mild water retention in the first 1-2 weeks of a cycle that often settles; vivid dreams or deeper sleep; a small rise in hunger 20-30 minutes after Ipamorelin, less marked than with GHRP-6; and mild irritation where it is injected.
Not ruled out: because no human trial has tested the pair, these summaries are carried over from the single compounds and from supervised clinic use of similar pairings, and long-term data past 90 days is limited even for the single compounds. Tingling or numbness in the hands is described as a sign of too much growth hormone or IGF-1; blood sugar can shift because growth hormone works against insulin; joint pain past the first two weeks is flagged; FDA review documents named rare allergic-type reactions; and long-term stimulation studies have flagged an underactive thyroid in a minority. Product quality varies between research suppliers, with a batch-matched certificate of analysis described as the minimum quality signal.
Who should avoid it
People with active cancer, a past cancer, or unscreened tumors: growth hormone and IGF-1 encourage cells to divide.
People with pituitary disease: listed as a group that should not use growth-hormone-stimulating peptides, with no further reason given.
People with diabetic retinopathy: listed as a group that should not use growth-hormone-stimulating peptides, with no further reason given.
People with severe kidney disease: listed as a group that should not use growth-hormone-stimulating peptides, with no further reason given.
People who are pregnant or breastfeeding: listed as a group that should not use growth-hormone-stimulating peptides, with no further reason given.
People with diabetes, insulin resistance or pre-diabetes: growth hormone works against insulin, so blood sugar needs close watching.
People with a known hypersensitivity to these peptides: FDA review documents named rare allergic-type reactions for both.
People with a thyroid condition: long-term growth hormone stimulation studies have flagged an underactive thyroid in a minority of users.
The reference sections on this page come from a compound library we import, not from our own review of the studies. Our own evidence grade appears only where an audit is linked. Research use only; nothing here is medical advice or a protocol.
5-Amino-1MQ (5-amino-1-methylquinolinium) is a small lab-made molecule, not a true peptide, though it is often sold alongside research peptides. It is studied for shrinking fat cells and raising NAD+ levels, and all evidence so far comes from cell and rodent studies, with no published human trial.
BPC-157 (Body Protection Compound 157) is a lab-made chain of 15 amino acids based on a sequence first found in human gastric juice. It is mostly studied in animal models of tendon, ligament, gut and blood-vessel injury, and human evidence is limited to three small pilots.
Cerluten is an oral peptide bioregulator referenced for nervous system support. Its proposed action, tissue-specific peptide bioregulation, is described as theoretical.
CJC-1295 with DAC is a lab-made 30-amino-acid copy of growth hormone-releasing hormone, altered so it attaches to albumin, a protein in the blood. It was studied in early human trials for its effect on growth hormone and IGF-1 levels.
Endoluten is a peptide bioregulator taken by mouth, listed in the reference library as pineal support. Its proposed action, tissue-specific peptide bioregulation, is described as theoretical.
GHK-Cu, or copper tripeptide-1, is a natural peptide of three amino acids bound to a copper ion, found in human blood plasma. It is studied for skin, hair and wound repair, mostly in cells and animals, with the strongest human evidence for topical use.